H. van den Ham

First name
H.
Middle name
A.
Last name
van den Ham
van den Dries, C. J., Pajouheshnia, R., van den Ham, H. A., Souverein, P., Moons, K. G. M., Hoes, A. W., et al. (2022). Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15534
View
van den Ham, H. A., Klungel, O. H., Leufkens, H. G., & van Staa, T. P. (2013). The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost. http://doi.org/10.1111/jth.12041
View
van den Ham, H. A., Klungel, O. H., Singer, D. E., Leufkens, H. G., & van Staa, T. P. (2015). Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. J Am Coll Cardiol. http://doi.org/10.1016/j.jacc.2015.08.033
View
Gieling, E. M., van den Ham, H. A., van Onzenoort, H., Bos, J., Kramers, C., de Boer, A., et al. (2017). Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.13265
View
Zhang, Y., Souverein, P. C., Gardarsdottir, H., van den Ham, H. A., van der Zee, A. H. M. -, & de Boer, A. (2020). Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.14227
View
van den Dries, C. J., van Doorn, S., Souverein, P., Pajouheshnia, R., Moons, K. G. M., Hoes, A. W., et al. (2020). The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation. TH Open. http://doi.org/10.1055/s-0040-1721499
View
Gulluoglu, R., Souverein, P. C., van den Ham, H. A., de Boer, A., & Komen, J. (2020). Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5181
View